Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study by Jimenez, Joaquin J. et al.
 Efficacy and Safety of a Low-level Laser Device in the Treatment
of Male and Female Pattern Hair Loss: A Multicenter,
Randomized, Sham Device-controlled, Double-blind Study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Jimenez, Joaquin J., Tongyu C. Wikramanayake, Wilma
Bergfeld, Maria Hordinsky, Janet G. Hickman, Michael R.
Hamblin, and Lawrence A. Schachner. 2014. “Efficacy and
Safety of a Low-level Laser Device in the Treatment of Male
and Female Pattern Hair Loss: A Multicenter, Randomized,
Sham Device-controlled, Double-blind Study.” American
Journal of Clinical Dermatology 15 (1): 115-127.
doi:10.1007/s40257-013-0060-6.
http://dx.doi.org/10.1007/s40257-013-0060-6.
Published Version doi:10.1007/s40257-013-0060-6
Accessed February 19, 2015 3:58:11 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152951
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA
ORIGINAL RESEARCH ARTICLE
Efficacy and Safety of a Low-level Laser Device in the Treatment
of Male and Female Pattern Hair Loss: A Multicenter,
Randomized, Sham Device-controlled, Double-blind Study
Joaquin J. Jimenez • Tongyu C. Wikramanayake •
Wilma Bergfeld • Maria Hordinsky • Janet G. Hickman •
Michael R. Hamblin • Lawrence A. Schachner
Published online: 29 January 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Significance Male and female pattern hair loss are com-
mon, chronic dermatologic disorders with limited thera-
peutic options. In recent years, a number of commercial
devices using low-level laser therapy have been promoted,
but there have been little peer-reviewed data on their
efficacy.
Objective To determine whether treatment with a low-
level laser device, the US FDA-cleared HairMax Laser-
comb, increases terminal hair density in both men and
women with pattern hair loss.
Methods Randomized, sham device-controlled, double-
blind clinical trials were conducted at multiple institutional
and private practices. A total of 146 male and 188 female
subjects with pattern hair loss were screened. A total of 128
male and 141 female subjects were randomized to receive
either a lasercomb (one of three models) or a sham device
in concealed sealed packets, and were treated on the whole
scalp three times a week for 26 weeks. Terminal hair
density of the target area was evaluated at baseline and at
16- and 26-week follow-ups, and analyzed to determine
whether the hypothesis formulated prior to data collection,
that lasercomb treatment would increase terminal hair
density, was correct. The site investigators and the subjects
remained blinded to the type of device they dispensed/
received throughout the study. The evaluator of masked
digital photographs was blinded to which trial arm the
subject belonged.
Results Seventy-eight, 63, 49, and 79 subjects were ran-
domized in four trials of 9-beam lasercomb treatment in
female subjects, 12-beam lasercomb treatment in female
subjects, 7-beam lasercomb treatment in male subjects, and
9- and 12-beam lasercomb treatment in male subjects,
compared with the sham device, respectively. Nineteen
female and 25 male subjects were lost to follow-up. Among
the remaining 122 female and 103 male subjects in the
Trial Registration: All trials were registered with http://www.
clinicaltrials.gov. Trial #1 (registration #NCT00981461), ‘‘Treatment
of Androgenetic Alopecia in Females, 9 Beam’’; Trial #2
(#NCT01016964), ‘‘Treatment of Androgenetic Alopecia in Females,
12 Beam’’; Trial #3 (#NCT00947505) and Trial #4 (#NCT00947219),
‘‘Treatment of Androgenetic Alopecia in Males’’.
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efficacy analysis, the mean terminal hair count at 26 weeks
increased from baseline by 20.2, 20.6, 18.4, 20.9, and 25.7
per cm2 in 9-beam lasercomb-treated female subjects,
12-beam lasercomb-treated female subjects, 7-beam laser-
comb-treated male subjects, and 9- and 12-beam lasercomb-
treated male subjects, respectively, compared with 2.8
(p \ 0.0001), 3.0 (p \ 0.0001), 1.6 (p = 0.0017), 9.4
(p = 0.0249), and 9.4 (p = 0.0028) in sham-treated sub-
jects (95 % confidence interval). The increase in terminal
hair density was independent of the age and sex of the
subject and the lasercomb model. Additionally, a higher
percentage of lasercomb-treated subjects reported overall
improvement of hair loss condition and thickness and full-
ness of hair in self-assessment, compared with sham-treated
subjects. No serious adverse events were reported in any
subject receiving the lasercomb in any of the four trials.
Conclusions and relevance We observed a statistically
significant difference in the increase in terminal hair den-
sity between lasercomb- and sham-treated subjects. No
serious adverse events were reported. Our results suggest
that low-level laser treatment may be an effective option to
treat pattern hair loss in both men and women. Additional
studies should be considered to determine the long-term
effects of low-level laser treatment on hair growth and
maintenance, and to optimize laser modality.
1 Introduction
Male and female pattern hair loss is a common, chronic
dermatologic disorder. Male pattern hair loss (MPHL, or
androgenetic alopecia, AGA) affects 50 % of men by
50 years of age, and the frequency and severity increase
with age [1]. MPHL is characterized by a dihy-
drotestosterone-dependent process with miniaturization of
terminal hair follicles (HFs) into vellus HFs [2]. The fre-
quency and severity of female pattern hair loss (FPHL) also
increase with age, with a prevalence of over 50 % in
women over the age of 80 years [3]. While the role of
androgens in all cases of FPHL is less certain, FPHL also
undergoes follicular miniaturization [1]. Current medical
treatments for pattern hair loss include topical minoxidil
(available in 2 % and 5 % solutions or 5 % foam, and
sometimes combined with other active ingredients such as
tretinoin), finasteride, dutasteride (US FDA approved for
the treatment of benign prostatic hyperplasia, and pre-
scribed off-label for treatment of MPHL), topical keto-
conazole, anti-androgens and estrogens (for FPHL), and
follicular unit transplantation [4]. In addition, there are
numerous oral supplements and topical treatments claimed
to have hair growth-promoting or anti-hair loss effects that
are marketed directly to the consumers, without indepen-
dent data supporting the claims.
In recent years, low-level laser/light therapy (LLLT), or
photobiomodulation or photobiostimulation, has been pro-
moted to prevent hair loss and stimulate hair growth in both
MPHL and FPHL. There have been a number of commer-
cially available devices designed for home use (daily or
several times a week), and they are relatively inexpensive
compared with current medical treatment and hair trans-
plantation surgery. However, there have been few peer-
reviewed data on efficacy [5]. In one published study, only
seven subjects with pattern hair loss (six female subjects and
one male subject) were evaluated upon treatment with a laser
‘‘hood’’ [6]. The study was not sham device-controlled and
the results did not reach statistical significance. A more
recent, randomized, double-blind, sham device-controlled
trial found ‘‘TOPHAT655’’ (a helmet-like device with lasers
and light-emitting diodes) treatment to increase terminal
hair count in pattern hair loss, but only male subjects were
included in the trial [7]. To date, the most comprehensive
published study is a randomized, double-blind, sham device-
controlled clinical trial of 110 male subjects showing that the
HairMax Lasercomb (Lexington International, LLC., Boca
Raton, FL, USA), FDA-cleared to treat pattern hair loss in
male subjects at the time, was effective in increasing ter-
minal hair density after 26 weeks of treatment [8]. The
device has since been approved for treating FPHL, though
there has been only one published study supporting the
efficacy, with limitations [9]. In this study, only seven
female subjects were included. They were given a lasercomb
to use for 6 months, and the terminal hair count was com-
pared between baseline and at the end of the study. The FDA
considered the LaserComb a medical device of ‘‘moderate
risk’’, therefore it only screened for safety, not efficacy.
Given the prevalence of MPHL and FPHL, their limited
medical treatment and the high costs of hair transplantation,
and the ready availability and user friendliness of LLLT
home devices, it is important to determine whether LLLT
can provide an effective alternative for pattern hair loss,
especially FPHL, for which no randomized, controlled trials
have been published. The objective of this study was to
determine the efficacy of LaserComb treatment of pattern
hair loss in both male and female subjects, in four random-
ized, multicenter, sham device-controlled, double-blind
prospective trials. A total of 122 female and 103 male sub-
jects were included in the efficacy analysis after 26 weeks of
treatment, and three lasercomb models were evaluated.
2 Methods
2.1 Patient Enrollment
The study protocol was evaluated under Good Clinical
Practice guidelines and approved by the authors’
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Institutional Review Boards (IRBs) or the Chesapeake
Research Review, Inc. All trials were registered with http://
www.clinicaltrials.gov. Prior to participation in the trials,
each subject provided a written informed consent. Partici-
pants received free evaluations at baseline and at follow-
ups. They were compensated for each visit and were given a
lasercomb at the end of the study (26-week visit). Subject
screening, recruitment, and follow-up were carried out at
multiple study sites: Trial #1 (registration #NCT00981461),
‘‘Treatment of Androgenetic Alopecia in Females, 9
Beam’’: International Dermatology Research, Inc. (Miami,
FL, USA), The Education & Research Foundation, Inc.
(Lynchburg, VA, USA); Trial #2 (#NCT01016964),
‘‘Treatment of Androgenetic Alopecia in Females, 12
Beam’’: The Cleveland Clinic Foundation (Cleveland, OH,
USA), University of Minnesota (Minneapolis, MN, USA),
University of Miami Miller School of Medicine (Miami,
FL, USA); Trial #3 (#NCT00947505) and Trial #4
(#NCT00947219), ‘‘Treatment of Androgenetic Alopecia in
Males’’: Dermatology Consulting Services (High Point,
NC, USA); Trials #1, #3, and #4: DermResearch, Inc.
(Austin, TX, USA), Skin Laser and Surgery Specialist
(Hillsborough, NJ, USA), and Palm Beach Research Center
(West Palm Beach, FL, USA). Full trial protocol is avail-
able upon request.
2.1.1 Study Inclusion/Exclusion Criteria
To be included in the trials, subjects must have been
healthy, 25–60 years of age, with active androgenetic hair
loss (Norwood–Hamilton classification of IIa–V for male
subjects [10] and Ludwig/Savin classification of I-4, II-1,
II-2, or frontal for female subjects) [11–13] and have
Fitzpatrick skin type I–IV [14]. Race/ethnicity information
was collected. Subjects must not have taken or used the
following medications within 6 months prior to screening:
minoxidil, finasteride (or any other 5a-reductase inhibi-
tors), medications with anti-androgenic properties (e.g.,
cyproterone acetate, spironolactone, ketoconazole, flutam-
ide, bicalutamide), topical estrogen, progesterone, tamox-
ifen, anabolic steroids, medication that can potentially
cause hypertrichosis (e.g., cyclosporine, diazoxide, phe-
nytoin, psoralens), oral glucocorticoids (inhaled glucocor-
ticoids were permitted), lithium, phenothiazines, or other
medications at the discretion of the investigators. Other
excluded medications were phytotherapy (e.g., saw pal-
metto) within 8 weeks, isotretinoin within the past year,
and anticoagulation use [other than aspirin (\325 mg every
day, which was stable for 3 months)]. Subjects were
excluded if they had malignancy in the target area within
5 years, active infection on the scalp, chronic dermatologic
conditions (e.g., eczema, psoriasis, infection) of the scalp
other than pattern hair loss, a history of poor wound healing
or keloid formation, a history of thyroid or other medical
condition that might influence hair growth and loss; human
immunodeficiency virus infection, possession of a pace-
maker, defibrillator, or other active implantable device; a
history of drug and/or alcohol abuse within the past
12 months; or any other medical conditions at the discre-
tion of the investigators. Pregnant female subjects or
female subjects planning on becoming pregnant during the
duration of the study were excluded. Subjects with a his-
tory of photosensitivity to laser light, hair transplantation,
scalp reduction, radiation to the scalp or chemotherapy
within the past year, current hair weave or tattooing, as
well as subjects with hair shorter than one-half inch or with
light-blonde hair were also excluded.
2.2 The Lasercomb and Sham Devices
Three different lasercomb configurations were evaluated
for similar laser dose rates. These models were designed to
meet varying marketing demands, and the FDA required
clinical studies on each model to ensure consistency of
results. The 7- and 9-beam lasercombs (HairMax Laser-
Comb, Lexington International, LLC) emit 7 or 9 red
laser beams (beam diameter \5 mm) at a wavelength of
655 nm (±5 %). The 12-beam dual model emits 6 beams at
a wavelength of 635 nm (±5 %) and 6 beams at 655 nm
(±5 %). The lasers for each device were identical in power
output, and the treatment time was adjusted for similar
laser dose rates: 15 min for the 7-beam model, 11 min for
the 9-beam model, and 8 min for the 12-beam model. Two
sham devices that emitted white light from light-emitting
diode bulbs had identical appearance as the 7- and 9-beam
lasercombs, and were used as controls for the 7-, and 9- or
12-beam lasercombs, respectively.
2.3 Study Design
Four multicenter prospective trials were designed, to be
randomized, sham controlled, and double blind. In Trials
#1 and #2, subjects with FPHL used a 9-beam (#1) or a
dual 12-beam (#2) lasercomb and sham device. In Trials #3
and #4, subjects with MPHL used a 7- (#3) or a 9- or
12-beam (#4) lasercomb and sham device.
Each study protocol was approved by institutional or the
Chesapeake IRB. Each Clinical Study Sponsor confirmed
performance in compliance with Good Clinical Practice
(GCP, as defined in CPMP/ICH/135/95), the Declaration of
Helsinki (with amendments), and local legal and regulatory
requirements. Lexington International LLC, as a company,
is and has been compliant and certified to ISO9001 and
ISO13485 Quality Standards. Lexington’s Clinical Study
Practices have been audited by the FDA and have con-
firmed to be in compliance with the FDA’s GCP. All
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studies were managed and audited by Palm Beach CRO
(Clinical Research Organization) and validated to be in
compliance with the approved protocol.
For subjects who met the inclusion and exclusion cri-
teria, at the baseline visit, a ‘‘target site’’ in the affected
scalp area was chosen using a 25 mm 9 25 mm plastic
template, and hair within this target site (25mm 9 25mm)
was clipped. The target site was then marked with a semi-
permanent tattoo using a professional tattooing machine
(K.P. Permanent Make-Up, Inc., Pomona, CA, USA), and
photographed.
Each subject was then provided with either a lasercomb
or a sham device. Randomization was generated by Eugene
R. Heyman (http://www.erhstats.com) using the SAS
PROC RAND method. For the 9- and 12-beam trial in male
subjects (#4), randomization was generated 1:1:1 with a
block size of 3. For all other trials, randomization was 2:1
with a block size of 3. The lasercomb and sham devices,
along with instructions, were provided to the site investi-
gators in sealed, sequentially numbered opaque packets in a
blinded manner, and were dispensed sequentially. Both the
site investigators and the subjects remained blinded to the
type of device they dispensed/received throughout the
study.
The subjects were instructed to apply the device three
times per week, with the beam on, to their entire scalp; the
duration of treatment specific for each device and their
respective sham control was included in the sealed packet
(15 min for the 7-beam model, 11 min for the 9-beam
model, and 8 min for the 12-beam model). Each subject
was required to keep a diary of usage, which was reviewed
by the site investigator at the time of office visits. The
study duration was 26 weeks, with clinical monitoring
visits at 8, 16, and 26 weeks. Dermatology scalp assess-
ment, safety assessment, global and macro digital imaging
after hair clipping, and computer-aided hair counts of the
target sites were performed by blinded investigators at
weeks 16 and 26, and compared with baseline.
2.3.1 Efficacy Evaluation
Change of terminal hair density (hair count/cm2) at
26 weeks from baseline was used as the endpoint to
evaluate the efficacy of lasercomb treatment in male and
female subjects with pattern hair loss. The Canfield Epi-
lume System was used for digital imaging of the target
sites at baseline and at weeks 16 and 26. All macro
photographs, with a 10-mm scale bar divided in 0.1-mm
increments, were labeled only by subject number and
uploaded to an online database. An independent evaluator
not connected to the clinical trials analyzed the uploaded
images and performed computer-assisted hair counts,
using the TrichoScience software (Tricholog, Moscow,
Russia). The evaluator was a hair transplant surgeon with
20 years of experience in evaluation of hair counts, and
was blinded to which trial arm the subject belonged, as
well as which images were from baseline and which were
from follow-up. Subjects also filled out questionnaires for
self-assessment of overall improvement of hair loss con-
dition and thickness and fullness of hair at the 16- and
26-week visits.
2.4 Statistical Analysis
Based on previous testing data on lasercomb use, change in
terminal hair count from baseline to study endpoint was
found to be a mean increase of just under 30 hairs/cm2 with
a standard deviation of 18.6 hairs/cm2. For the sample size
calculation, the assumed standard deviation was 20 hairs/
cm2 and the treatment difference was assumed to be 17
hairs/cm2. Each trial had a planned enrollment of 60 sub-
jects in a 2:1 allocation of lasercomb:sham device to
achieve at least 80 % power while allowing a 10 % drop-
out rate. In Trials #1–3, subjects were randomized to a 2:1
allocation of the lasercomb:sham device. In Trial #4, sub-
jects were randomized in a 1:1:1 allocation of the
9-beam:12-beam:sham device. For subject enrollment,
continuous variables (e.g., age) were analyzed with a one-
way analysis of variance and categorical variables with the
Fisher’s exact test.
The primary efficacy endpoint was the change in ter-
minal hair density within the target area at 26 weeks from
baseline, assessed in all subjects with baseline and at least
one post-randomization efficacy evaluation. The laser-
comb-treated group was compared with the sham device
group using least squares mean with two-sided at a 5 %
level of significance. The primary analysis of efficacy was
an analysis of co-variance, which modeled terminal hair
density as a function of treatment group, study center, age
(as a continuous variable), and Fitzpatrick skin type (as a
categorical variable). The secondary efficacy endpoint was
the categorical change in terminal hair density from base-
line, analyzed using the Cochran–Mantel–Haenszel row
mean score test with integer scores stratified by study site.
Cochran’s Q test was performed to analyze the homoge-
neity of results across genders, all trials, and all lasercomb
models. Subject self-assessment was also evaluated using
the Cochran–Mantel–Haenszel row mean score test with
integer scores stratified by site. The DerSimonian–Laird
approach was used to perform the meta-analysis homoge-
neity assessment. All statistical analyses were contracted to
Stat-Tech Services, LLC (Chapel Hill, NC, USA). For
evaluation of safety, adverse events were summarized and
each event was evaluated for frequency.
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3 Results
3.1 Study Population
A total of 188 female and 146 male subjects were screened,
and 141 female and 128 male subjects were randomized to
receive the lasercomb or sham device. Of these subjects, 19
female and 25 male subjects were lost to follow-up, leaving
122 female and 103 male subjects completing at least one
follow-up. Sixty-five and 57 subjects (122 total) were
included in the efficacy evaluation for Trials #1 and #2 (the
female trials evaluating the 9-beam and dual 12-beam
lasercomb, respectively) (Fig. 1; Table 1), and 38 and 65
subjects (103 total) were included in the efficacy evaluation
for Trials #3 and #4 (the male trials evaluating the 7- and
the 9- or 12-beam lasercomb, respectively) (Fig. 1;
Table 2). There were no statistically significant differences
in demographic characteristics or hair loss features
between the lasercomb and sham group in any of the four
trials at baseline (Tables 1 and 2). The age of the subjects
was 25–61 years, and 94.7 % were Caucasian. The last
follow-up was conducted after 26 weeks of treatment, an
accepted standard for clinical trials on hair growth.
3.2 Analysis of Efficacy
The trials were designed to be randomized and double
blind. Data from different study sites were pooled for sta-
tistical analysis. All the randomized subjects who had a
baseline and at least one post-randomization evaluation
were included in the efficacy analysis (Fig. 1). To account
for dropouts thereafter, all data are presented in last
observation carried forward for the analysis of covariance
for Trials #1 and #4.
3.2.1 Primary Efficacy Analysis
In Trial #1, a significant difference in terminal hair density
change from baseline was observed between the 9-beam
lasercomb- and sham-treated female subjects at 26 weeks
(p \ 0.0001) (Fig. 2a). The lasercomb-treated subjects
showed a much higher increase in terminal hair density
compared with sham-treated subjects, with a mean of 20.2
(±11.2 standard deviation [SD]) versus 2.8 (±16.5 SD) per
cm2 (Fig. 2a). Similar improvement in terminal hair den-
sity was observed with the 12-beam lasercomb treatment in
Trial #2 (Fig. 2b). The lasercomb-treated female subjects
Subjects screened
N=117
Study #1
Female, 9-beam
Did not meet criteria 
n=39
Randomized: n=78
Efficacy n=65
16-week follow-up:
n=65
9-beam n=43, 
Sham n=22
Lost to follow-up/ 
consent 
withdrawal: n=13
26-week follow-up:
9-beam n=42, 
Sham n=21
Lost to follow-up: 
n=2
Study #2
Female, 12-beam
Subjects screened 
N=71
Did not meet criteria
n=8
Efficacy n=57
16-week follow-up:
n=57
12-beam n=39, 
Sham n=18
Lost to follow-up/ 
consent withdrawal:
n=6
26-week follow-up:
12-beam n=39, 
Sham n=18
Lost to follow-up: 
n=0
Randomized: n=63
Study #3
Male, 7-beam
Subjects screened 
N=57
Did not meet criteria
n=8
Efficacy n=38
16-week follow-up:
n=38
7-beam n=24, 
Sham n=14
Lost to follow-up/
consent withdrawal: 
n=11
26-week follow-up:
7-beam n=24, 
Sham n=14
Lost to follow-up: 
n=0
Randomized: n=49
Study #4
Male, 9- or 12-beam
Subjects screened 
N=89
Did not meet criteria
n=10
Efficacy n=65
16-week follow-up:
n=65
9-beam n=21,
12-beam n=22, 
Sham n=22
Lost to follow-up/
consent withdrawal: 
n=14
26-week follow-up:
9-beam n=21,
12-beam n=19, 
Sham n=21
Lost to follow-up: 
n=4
Randomized: n=79
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Fig. 1 Profile of the four
randomized, sham-controlled
trials of lasercomb treatment of
male and female pattern hair
loss. Dates of recruitments are
indicated
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had a mean increase in terminal hair density of 20.6 (±11.6
SD) compared with 3.0 (±9.3 SD) for the sham group
(Fig. 2b). Overall, primary efficacy analysis showed the
difference in terminal hair density change at 26 weeks
from baseline between lasercomb and sham treatment was
highly significant (p \ 0.0001) in both female trials
(Fig. 2a, b). Similarly, statistically significant improvement
was observed with lasercomb treatment compared with
sham treatment in both male trials (Trial #3, 7-beam
lasercomb vs. sham, p = 0.0017, Fig. 2c; Trial #4, 9- and
12-beam lasercombs vs. sham, p = 0.0249 and
p = 0.0028, for the 9- and 12-beam lasercombs, respec-
tively, Fig. 2d).
3.2.2 Secondary Efficacy Analyses
Secondary efficacy analyses included categorical summa-
ries and covariate analyses of changes in terminal hair
density from baseline. In Trial #1, 41 of 43 (95 %) of the
9-beam lasercomb-treated female subjects had hair density
improvement of[5 hairs/cm2 at 26 weeks while only 7 of
22 (32 %) sham-treated female subjects did (p \ 0.0001)
(Fig. 2e). Additionally, none of the 43 lasercomb-treated
subjects showed decreased hair density as opposed to 11 of
22 (50 %) sham-treated subjects (Fig. 2e). Analysis of data
collected at 16 weeks revealed similar results (data not
shown). In Trial #2, 37 of 39 (95 %) of the 12-beam
lasercomb-treated female subjects had hair density
improvement of [5 hairs/cm2 while only 6 of 18 (33 %)
sham-treated female subjects did (p \ 0.0001) (Fig. 2f).
Although 7 of 18 (39 %) sham-treated subjects showed
decreased hair density, only 1 of 39 (3 %) lasercomb-
treated subjects did (Fig. 2f).
In Trial #3, 20 of 24 (83 %) of the 7-beam lasercomb-
treated male subjects had hair density improvement of [5
hairs/cm2, while only 6 of 14 (43 %) sham-treated male
subjects did (p = 0.0033) (Fig. 2g). Additionally, only 2 of
the 24 (8 %) lasercomb-treated male subjects showed
Table 1 Demographic characteristics of female subjects at baseline for the 9- and 12-beam lasercomb trials
Trial #1 (n = 65) Trial #2 (n = 57)
9-beam lasercomb Sham p value 12-beam lasercomb Sham p value
Number of subjects 43 22 39 18
Age (years) 0.8261 0.9102
Mean age (SD) 49.3 (9.1) 49.8 (7.3) 48.7 (10.2) 49.1 (8.3)
Median age 52 49 50 49
Range 29–60 37–60 26–61 33–60
Race, n (%) 1.0000 1.0000
Caucasian 39 (90.7 %) 20 (90.9 %) 37 (94.9 %) 18 (100.0 %)
African American 1 (2.3 %) 0 (0 %) 1 (2.6 %) 0 (0 %)
Native American 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Alaska Native 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Asia/Pacific Islander 2 (4.7 %) 1 (4.5 %) 1 (2.6 %) 0 (0 %)
Other 1 (2.3 %) 1 (4.5 %) 0 (0 %) 0 (0 %)
Ethnicity, n (%) 0.2773 1.0000
Hispanic or Latino 13 (30.2 %) 10 (45.5 %) 10 (25.6 %) 4 (22.2 %)
Not Hispanic or Latino 30 (69.8 %) 12 (54.5 %) 29 (74.4 %) 14 (77.8 %)
Ludwig/Savin classification, n (%) 0.6513 0.2926
I-4 12 (27.9 %) 3 (13.6 %) 21 (53.8 %) 6 (33.3 %)
II-1 11 (25.6 %) 7 (31.8 %) 11 (28.2 %) 6 (33.3 %)
II-2 15 (34.9 %) 9 (40.9 %) 6 (15.4 %) 4 (22.2 %)
Frontal 5 (11.6 %) 3 (13.6 %) 1 (2.6 %) 2 (11.1 %)
Fitzpatrick skin type, n (%) 1.0000 0.7606
I 0 (0 %) 0 (0 %) 2 (5.1 %) 0 (0 %)
II 15 (34.9 %) 7 (31.8 %) 11 (28.2 %) 4 (22.2 %)
III 20 (46.5 %) 11 (50.0 %) 14 (35.9 %) 9 (50.0 %)
IV 8 (18.6 %) 4 (18.2 %) 12 (30.8 %) 5 (27.8 %)
Mean baseline hair counta (SD) 162.6 (46.2) 155.7 (43.5) 142.2 (40.5) 168.4 (41.1)
a Number of terminal hairs per cm2 in the target area
SD standard deviation
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decreased hair density, while 6 of 14 (43 %) sham-treated
subjects did (Fig. 2g). In Trial #4, lasercomb-treated male
subjects showed a higher percentage for hair density
improvement of[5 hairs/cm2 with either lasercomb model
(86 % for the 9-beam model and 82 % for the 12-beam
model) than the sham-treated subjects (59 %) (Fig. 2h).
Whereas 9 of 22 (41 %) sham-treated subjects showed
decreased hair density, only 3 of 21 (14 %) 9-beam laser-
comb-treated subjects and 4 of 22 (18 %) 12-beam laser-
comb-treated subjects did (p = 0.0033) (Fig. 2h).
Overall, we observed significant categorical improve-
ment in terminal hair density with lasercomb treatment
versus control (Fig. 2e–h). Taken together, all four trials
using three different lasercomb models in both male and
female subjects showed improvement in terminal hair
density that was highly statistically significant, as well as
categorical improvement, with lasercomb treatment com-
pared with sham treatment at 26 weeks.
3.2.3 Subject Self-Assessment
A higher percentage of lasercomb-treated subjects reported
overall improvement of hair loss condition and thickness
and fullness of hair in self-assessment, compared with
sham-treated subjects (Table 3). In Trial #1, statistical
significance was reached for the assessment of both the
overall improvement of hair loss condition and thickness
and fullness of hair. Results in Trial #2 did not reach sta-
tistical significance. In the pooled male subject trials,
assessment of the thickness and fullness of hair reached
statistical significance, but not the overall improvement of
hair loss condition (Table 3).
Table 2 Demographic characteristics of male subjects at baseline for the 7-, 9-, or 12-beam lasercomb trials
Trial #3 (n = 38) Trial #4 (n = 65)
7-beam
lasercomb
Sham p value 9-beam
lasercomb
12-beam
lasercomb
Sham p value
Number of subjects 24 14 21 22 22
Age (years) 0.0327 0.7100
Mean age (SD) 47.8 (9.0) 40.9 (9.5) 45.6 (9.3) 47.9 (9.6) 45.9 (10.4)
Median age 48 41.5 50 50.5 47
Range 26–59 25–55 26–58 26–59 30–61
Race, n (%) 1.0000 1.0000
Caucasian 23 (95.8 %) 13 (92.9 %) 21 (100.0 %) 21 (95.5 %) 21 (95.5 %)
African American 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Native American 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Alaska native 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Asia/Pacific islander 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (4.5 %)
Other 1 (4.2 %) 1 (7.1 %) 0 (0 %) 1 (4.5 %) 0 (0 %)
Ethnicity, n (%) 0.6497 0.041
Hispanic or Latino 3 (12.5 %) 3 (21.4 %) 4 (19.0 %) 1 (4.5 %) 0 (0 %)
Not Hispanic or Latino 21 (87.5 %) 11 (78.6 %) 17 (81.0 %) 21 (95.5 %) 22 (100.0 %)
Norwood–Hamilton classification,
n (%)
0.9130 1.0000
II 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (4.5 %)
III 10 (41.7 %) 5 (35.7 %) 10 (47.6 %) 10 (45.5 %) 10 (45.5 %)
IV 9 (37.5 %) 5 (35.7 %) 8 (38.1 %) 9 (40.9 %) 7 (31.8 %)
V 5 (20.8 %) 4 (28.6 %) 3 (14.3 %) 3 (13.6 %) 4 (18.2 %)
Fitzpatrick skin type (%) 0.7904 0.998
I 1 (4.2 %) 0 (0 %) 3 (14.3 %) 2 (9.1 %) 2 (9.1 %)
II 3 (12.5 %) 3 (21.4 %) 9 (42.9 %) 10 (45.5 %) 9 (40.9 %)
III 12 (50.0 %) 5 (35.7 %) 7 (33.3 %) 8 (36.4 %) 9 (40.9 %)
IV 8 (33.3 %) 6 (42.9 %) 2 (9.5 %) 2 (9.1 %) 2 (9.1 %)
Mean baseline hair counta (SD) 211.5 (54.0) 216.6 (34.8) 163.3 (69.4) 151.5 (42.4) 171.4 (62.3)
a Number of terminal hairs per cm2 in the target area
SD standard deviation
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3.2.4 Meta-Analysis of the Effects of Lasercomb Model,
Study Duration, and Gender
Meta-analyses were conducted to provide an overall
assessment of the individual study results. The overall
results showed the least squares mean difference of change
in terminal hair density of 15.27 (standard error 1.781) at
26 weeks from baseline between lasercomb- and sham
treated subjects, which was highly statistically significant
(p \ 0.0001). The homogeneity assessment results were
non-significant (p = 0.6188). These results indicated that
compared with sham treatment, lasercomb treatment
resulted in a statistically significant increase in terminal
hair density across the trials, independent of the lasercomb
model (7- and 9-beam 655 nm ± 5 % laser and 12-beam
635 nm and 655 nm ± 5 % laser) and the sex of the
subject.
Before and after global photographs (Fig. 3a, b) and
macrophotographs (Fig. 3c, d) demonstrated increases in
terminal hair density, most likely through the conversion of
vellus or intermediate follicles to terminal follicles or from
resting telogen follicles to active anagen follicles.
In summary, efficacy analysis showed a statistically
significant increase in terminal hair density after 26 weeks
of lasercomb treatment compared with sham treatment.
The mean increase in terminal hair density was higher
(statistically significant) in lasercomb-treated subjects than
in sham-treated subjects. Additionally, a higher percentage
of lasercomb-treated subjects showed categorical hair
density improvement ([5 hairs/cm2) at 26 weeks, com-
pared with sham-treated subjects. Such improvement was
observed in all four trials, and independent of the sex and
age of the subject, and independent of the lasercomb model
when similar laser dose rates were delivered. A higher
percentage of lasercomb-treated subjects reported overall
improvement of hair loss condition and thickness and
fullness of hair in self-assessment, though the results did
not always reach statistical significance.
3.3 Safety and Tolerability
No serious adverse events were reported in any subject
receiving the lasercomb in any of the four trials. Reported
lasercomb-related adverse events included dry skin
(5.1 %), pruritus (2.5 %), scalp tenderness (1.3 %), irrita-
tion (1.3 %), and a warm sensation at the site (1.3 %). No
subjects experienced an adverse event that resulted in the
discontinuation of the study device, or interruption of the
study. No adverse events had an impact on the study device
use. There were no significant differences in active device
adverse events as recorded by device type.
4 Discussion
Pattern hair loss may affect up to 70 % of men and 50 % of
women at some point in their lifetime [3, 4]. There has
been an urgent need to determine whether LLLT home
devices, which have been widely promoted for the treat-
ment of MPHL and FPHL despite few randomized, con-
trolled trials, can provide an effective alternative for
patients with pattern hair loss, especially female patients.
In this study, through four randomized, multicenter, sham
device-controlled and double-blind clinical trials, we have
shown that 26 weeks of treatment with the FDA-cleared
HairMax LaserComb, compared with sham treatment,
Fig. 3 Male and female pattern
hair loss before and after
lasercomb treatment. Global
photographs of a female subject,
at baseline (a) and after
26 weeks (b) of the 12-beam
lasercomb treatment.
Macrophotographs of a male
subject, at baseline (c) and after
26 weeks (d) of the 9-beam
lasercomb treatment. Increased
hair count through conversion
of vellus or intermediate
follicles to active follicles
producing terminal hair (ovals)
or resting telogen to active
anagen follicles (rectangles) is
highlighted
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resulted in a statistically significant terminal hair density
increase. Our results not only verified the effective treat-
ment of MPHL reported previously [8], but also showed
treatment efficacy in female subjects, and demonstrated
that the treatment efficacy was independent of the laser
configurations tested when similar laser dose rates were
delivered. No serious adverse events were reported in any
subject receiving lasercomb treatment in any of the four
trials.
We have observed increased terminal hair density likely
through both conversion of vellus or intermediate follicles
to active follicles producing terminal hair and conversion of
resting telogen follicles to active anagen follicles (Fig. 3c,
d). The exact mechanisms of such conversions by LLLT
remain unknown. Commonly used LLLT encompasses a
wavelength of 500–1,100 nm and delivers fluences of
1–4 J/cm2 with a power density of 3–90 mW/cm2, and has
demonstrated beneficial effects in various conditions
including wound healing, joint pain relief, mucositis pre-
vention and treatment, and skin conditions [15–22]. Based
on anecdotal experience, LLLT of 650–900 nm wave-
lengths at 5 mW has been suggested to be an effective
treatment option for male and female patients with pattern
hair loss [23], though comprehensive studies evaluating
laser modality are lacking. Whereas the exact mechanisms
of hair growth stimulation by LLLT remain unknown,
LLLT has been proposed to accelerate mitosis [24], and
may stimulate HF stem cells or activate follicular kerati-
nocytes. Additionally, laser light may alter cell metabolism
through photodissociation of inhibitory nitric oxide from
cytochrome c oxidase [25] (unit IV in the respiratory chain
of mitochondria), causing increased ATP production and
cellular activity [26]. Furthermore, resolution of inflam-
mation may be one potential mechanism of hair growth
stimulation by LLLT in AGA [27–32]. In vitro and in vivo
trials of LLLT have shown decreased inflammatory pros-
taglandin E-2 [32] and proinflammatory cytokines [30], and
in contrast, increased anti-inflammatory cytokines trans-
forming growth factor-beta 1 and interleukin-10 [27, 28].
Results from the present investigation are consistent
with the previous study of the 9-beam lasercomb in male
AGA subjects by Leavitt et al. [8]. Both studies demon-
strated a higher increase in terminal hair density with
lasercomb treatment versus sham treatment, which was
statistically significant, with a positive safety profile for the
device. However, the current study enrolled both male and
female subjects, and tested a range of laser configurations
(8 min of treatment for the 12-beam model, 11 min for the
9-beam model, and 15 min for the 7-beam model, so that
the three models gave similar laser dose rates per treat-
ment), making it a more comprehensive study. While we
found the lasercomb to be also efficacious in increasing
terminal hair count in female subjects, we feel we cannot
directly compare our results with another lasercomb study
of female subjects (n = 7) as the baseline hair counts were
too different (71–307/cm2 vs. 8–32/cm2) [9]. A recent
study described the high efficacy of treating MPHL using a
helmet-like low-level laser device, called TOPHAT, in a
randomized, double-blind, controlled trial [7]. While the
TOPHAT study was for 16 weeks with treatment every
other day for a total of 60 treatments versus 78 treatments
in total in this lasercomb study, the laser dose rates per
treatment in the TOPHAT study were much higher (there
were 21 5-mW laser units). Future studies are required to
optimize laser modality and treatment regimen for hair
growth and maintenance.
The increase in terminal hair density per cm2 observed
in our study is comparable to that observed in a 6-month
randomized, investigator-blinded, controlled trial of 5 %
minoxidil solution in MPHL [33], but lower than that
observed in 48-week studies of 5 % and 2 % minoxidil
topical solution in MPHL [34] and FPHL [35]. Our results
in the increase in terminal hair count are comparable to
1 mg/day finasteride treatment in some MPHL trials [36,
37], but less efficacious than longer term trials [38].
LLLT may provide a promising treatment option for
patients who do not respond to either finasteride or
minoxidil, and who do not want to undergo hair trans-
plantation. Additionally, while topical minoxidil solution
or foam is widely used to treat pattern hair loss and is
generally well tolerated [39], the treatment needs to be
applied once or twice daily, and be in contact with the scalp
for at least 4 h. Such application can be impractical for
many users, leading to noncompliance and reduced effi-
cacy. As an alternative, the lasercomb treatment is safe and
easy to apply, with 8–15 min of treatment three times per
week, and leaves no residue on the scalp. Such user
friendliness of the lasercomb may lead to better patient
compliance and improved efficacy. Future studies to
modulate laser modality and treatment regimen will help
optimize hair growth stimulation and maintenance by low-
level laser.
5 Conclusions
In four randomized, double-blind, sham-controlled trials of
MPHL and FPHL, we detected a statistically significant
increase in terminal hair density after 26 weeks of laser-
comb treatment compared with sham treatment. Such
improvement was independent of the sex and age of the
subject, and independent of the lasercomb model when
similar laser dose rates were delivered. A higher percentage
of lasercomb-treated subjects reported overall
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improvement of hair loss condition and thickness and
fullness of hair in self-assessment, though the results did
not always reach statistical significance. Increase in ter-
minal hair count was comparable to the short-term trials of
5 % minoxidil topical solution and 1 mg/day finasteride,
but less efficacious than longer term (C1 year) trials.
Further clinical trials are needed to define the optimal
duration of treatment, the duration of response, and the use
of the lasercomb in other alopecia conditions.
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